` UCB (Ucb SA) vs DAX Index Comparison - Alpha Spread

UCB
vs
DAX Index

Over the past 12 months, UCB has underperformed DAX Index, delivering a return of 18% compared to the DAX Index's 22% growth.

Stocks Performance
UCB vs DAX Index

Loading

Performance Gap
UCB vs DAX Index

Loading
UCB
DAX Index
Difference

Performance By Year
UCB vs DAX Index

Loading
UCB
DAX Index
Add Stock

Competitors Performance
Ucb SA vs Peers

DAX Index
UCB
LLY
JNJ
NOVO B
ROG
Add Stock

Ucb SA
Glance View

Market Cap
27.9B EUR
Industry
Pharmaceuticals

UCB SA, a Belgian multinational biopharmaceutical company, stands at the forefront of innovation in the medical field, committed to creating value by discovering new ways to treat severe diseases. Founded in 1928, UCB has transformed over the decades from its initial focus in chemicals to pioneering developments in advanced therapeutics targeting central nervous system disorders and immunology. Anchored by a robust research pipeline and a keen focus on rare diseases and specialty care, UCB has established a strong presence globally, reflecting its strategic pivot toward patient-centric approaches. With primary research facilities stationed in Braine-l'Alleud, Belgium, and Slough, UK, the company's scientific endeavors are bolstered by collaborations with research institutions worldwide, fostering an environment ripe for breakthrough discoveries. Financially, UCB's revenue streams are predominantly derived from its established portfolio of blockbuster drugs, such as Cimzia, Vimpat, and Keppra, which serve as critical lifelines for patients dealing with autoimmune diseases, epilepsy, and other chronic conditions. The company thrives on a dynamic business model that combines in-house scientific research with strategic partnerships and acquisitions to enhance its competitive edge. This synergy not only facilitates sustained growth in its core markets but also drives expansion into emerging ones, underscoring its global reach. By reinvesting substantial portions of its earnings into research and development, UCB ensures a steady pipeline of new products, thereby maintaining its stature in the highly competitive biopharmaceutical landscape. Through such strategic maneuvers, UCB aligns its operations with the overarching goal of delivering transformative therapies that improve the quality of life for patients around the world.

UCB Intrinsic Value
172.72 EUR
Undervaluation 15%
Intrinsic Value
Price
Back to Top